Evidence map›Paper›PMID 27147509›Full record

ReviewCurrent cardiology reports2016

Arrhythmogenic Right Ventricular Cardiomyopathy: Risk Stratification and Indications for Defibrillator Therapy.

Alessandro Zorzi, Ilaria Rigato, Barbara Bauce, Kalliopi Pilichou, Cristina Basso, Gaetano Thiene, Sabino Iliceto, Domenico Corrado

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Arrhythmogenic Cardiomyopathy and Sports Activity.Journal of cardiovascular translational research · 2020
    Review
  4. Review
  5. Article
  6. Article
  7. Inherited cardiomyopathies and sports participation.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2018
    Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alessandro ZorziDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
Ilaria RigatoDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
Barbara BauceDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
Kalliopi PilichouDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
Cristina BassoDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
Gaetano ThieneDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
Sabino IlicetoDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
Domenico CorradoDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy. domenico.corrado@unipd.it.
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined disease which predisposes to life-threatening ventricular arrhythmias. The main goal of ARVC therapy is prevention of sudden cardiac death (SCD). Implantable cardioverter defibrillator (ICD) is the most effective therapy for interruption of potentially lethal ventricular tachyarrhythmias. Despite its life-saving potential, ICD implantation is associated with a high rate of complications and significant impact on quality of life. Accurate risk stratification is needed to identify individuals who most benefit from the therapy. While there is general agreement that patients with a history of cardiac arrest or hemodynamically unstable ventricular tachycardia are at high risk of SCD and needs an ICD, indications for primary prevention remain a matter of debate. The article reviews the available scientific evidence and guidelines that may help to stratify the arrhythmic risk of ARVC patients and guide ICD implantation. Other therapeutic strategies, either alternative or additional to ICD, will be also addressed.

Indexed as

Defibrillators, ImplantableArrhythmogenic Right Ventricular DysplasiaDeath, Sudden, CardiacHumansRisk AssessmentRisk FactorsSurvival AnalysisGuidelinesImplantable cardioverter defibrillatorSudden cardiac deathVentricular arrhythmiasVentricular fibrillationVentricular tachycardia

Identifiers

PMID27147509
OpenAlexW2345758717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.